Clinical Deep Dives

Med School Audio - Medical Knowledge Reimagined & Learning Made Memorable.
  • 0.0 (0)
  • Medicine
  • Updated daily

Clinical Deep Dives is a Medlock Holmes podcast for clinicians and learners who want understanding, not just information. Using classic medical and surgical texts as a guide and the generative power of AI, each episode explores ideas with curiosity and clarity, designed for learning on the move and knowledge that actually sticks. drmanaankarray.substack.com

  1. 1 day ago

    PSYCH 126: Post-Traumatic Stress Disorder

    Medlock Holmes enters an immense Neo-Victorian institution called The Citadel of the Unfinished Alarm. At the centre is a vast clock frozen at the moment of trauma. Outside the citadel, the danger has passed. Inside, however, bells continue to ring. A veteran ducks at the sound of a car backfiring. A survivor avoids a street that resembles the place of an assault. Another wakes from the same nightmare night after night. A fourth scans every room for exits. Holmes immediately recognises the defining paradox of post-traumatic stress disorder: The event belongs to the past, but the nervous system continues to respond as though danger remains present. PTSD is classified as a trauma- and stressor-related disorder. Diagnosis requires exposure to actual or threatened death, serious injury or sexual violence, followed by characteristic symptoms lasting longer than one month and causing meaningful distress or impairment. Those symptoms fall into four major clusters: Intrusion. Avoidance. Negative alterations in cognition and mood. Alterations in arousal and reactivity. Intrusive memories are not ordinary recollections. They possess a disturbing “here and now” quality. Flashbacks, nightmares and physiological reactions to reminders can make the past feel emotionally immediate. Avoidance then emerges as an understandable attempt to control this intrusion. The person avoids places, people, conversations, memories, feelings and bodily sensations associated with trauma. But avoidance comes at a cost. It prevents the nervous system from learning: “This reminder is not the original danger.” Fear spreads. One battlefield cue becomes avoidance of uniforms, crowds, loud noises and unfamiliar places. Life becomes increasingly organised around preventing surprises. The third cluster alters the person’s world beyond the trauma itself. I cannot trust anyone. The world is completely dangerous. I should have prevented it. Something in me is permanently damaged. Interests fade. Positive emotion becomes difficult. Relationships become distant. Guilt, shame and emotional numbing can replace the person’s previous assumptions about self and world. Meanwhile, the alarm system remains sensitised. Hypervigilance. Exaggerated startle. Poor sleep. Irritability. Concentration difficulty. Reckless behaviour. The syndrome therefore becomes more than fear of a memory. It is a disturbance of threat detection, contextual processing, emotion regulation, attention, learning and recovery. The brain-circuit diagram on page 25 captures this particularly well. Four interacting systems are highlighted: emotion regulation and executive function, threat and salience detection, contextual processing, and fear learning. Rather than one damaged “trauma centre”, PTSD involves altered communication among the prefrontal cortex, anterior cingulate, insula, amygdala, hippocampus, thalamus and related structures. Holmes reaches the amygdala first. It rapidly tags potential threat. The insula monitors salient internal and external signals. The dorsal anterior cingulate helps orient attention towards danger. But prefrontal regulatory systems that should inhibit unnecessary alarm may function less efficiently. The hippocampus supplies another critical function: context. A loud noise in combat meant one thing. A loud noise at home years later means another. PTSD can impair the ability to use context to update the meaning of the signal. This is why the chapter presents PTSD as, in part, a disorder of recovery. Many people show substantial symptoms immediately after trauma. Most improve. Those who develop PTSD fail to follow the expected trajectory of extinction, contextual updating and restoration of safety. Fear conditioning provides one model. During trauma, previously neutral stimuli become associated with extreme threat. Later, those stimuli can trigger defensive responses even when the original threat is absent. Normally, repeated safe encounters produce extinction learning. But PTSD is associated with impaired extinction and impaired retention of extinction. The person may learn safety briefly and then lose access to that learning when reminded of danger. Holmes also discovers that biology before the trauma matters. PTSD does not occur in everyone who experiences trauma. Risk reflects interactions among: * previous trauma * childhood adversity * genetic vulnerability * social support * severity of exposure * peri-traumatic responses * continuing stress * post-trauma environment. The traumatic event is therefore necessary but not sufficient. Genetics contribute, but there is no single PTSD gene. The disorder has a polygenic architecture, with environmental experiences and epigenetic regulation shaping biological vulnerability. The neuroendocrine system also becomes involved. Noradrenergic hyper-reactivity may strengthen traumatic memory and contribute to hypervigilance and nightmares. Cortisol regulation is altered in some patients. Neuropeptide Y appears associated with resilience. GABA-modulating neurosteroids may be reduced. Dopamine contributes to stress responses and disrupted reward. Sleep becomes another crucial clue. Up to 90% of people with PTSD report sleep disturbance. Nightmares and fragmented sleep do not merely accompany the disorder; disrupted sleep may interfere with emotional memory processing and fear extinction, potentially helping maintain PTSD. Holmes then turns from mechanism to treatment. Trauma-focused psychotherapies have the strongest evidence. Prolonged Exposure asks the patient to approach rather than avoid trauma memories and safe reminders. Cognitive Processing Therapy examines distorted beliefs involving danger, blame, guilt and permanent damage. EMDR combines trauma recall with structured sensory stimulation. Other therapies can also help, including present-centred and interpersonal approaches in selected patients. Medication provides another route. SSRIs have the strongest evidence, particularly sertraline and paroxetine, while venlafaxine is also supported. Prazosin has been used particularly for trauma-related nightmares. Benzodiazepines, despite their intuitive appeal for acute distress, are poorly supported and may interfere with trauma recovery mechanisms. The chapter also explores emerging approaches including rTMS, neurofeedback, cannabinoids, glutamatergic interventions and MDMA-assisted psychotherapy, while emphasising the limits of current evidence. Holmes finally enters the room marked: PREVENTION. Here he discovers one of the most important lessons in trauma care. Immediate emotional debriefing was once widely believed to prevent PTSD. It does not. Routine single-session psychological debriefing can be ineffective and may even interfere with natural recovery. Most trauma survivors do not require immediate trauma processing. What they often need first is: safety, practical assistance, human contact, sleep, shelter, information and monitoring. Early targeted CBT can help people who have already developed significant acute traumatic stress symptoms. But blanket intervention for everyone exposed to trauma is neither necessary nor supported. Holmes leaves the citadel with a final insight. PTSD is not simply the presence of a terrible memory. It is the failure of that memory to acquire an appropriate timestamp. The nervous system knows what happened. What it struggles to learn is: “It happened then. I am here now.” Recovery therefore requires more than forgetting. It requires rebuilding the capacity to distinguish: memory from current danger, reminder from recurrence, and the world that contained the trauma from the world that exists today. Key Takeaways 1. PTSD Is a Trauma- and Stressor-Related Disorder PTSD requires a clear relationship between current symptoms and exposure to a qualifying traumatic event. Unlike most psychiatric diagnoses, the triggering event is part of the diagnostic definition. 2. What Qualifies as Trauma? Criterion A includes exposure to actual or threatened: DEATH SERIOUS INJURY or SEXUAL VIOLENCE through: * directly experiencing it * witnessing it * learning that it happened violently or accidentally to a close person * repeated or extreme occupational exposure to aversive details. Routine exposure through television or social media does not qualify unless it occurs as part of professional duties. 3. The Four Core Symptom Clusters PTSD requires symptoms across four domains: B - Intrusion C - Avoidance D - Negative Cognitions and Mood E - Altered Arousal and Reactivity The pattern must persist for: MORE THAN 1 MONTH and cause clinically significant distress or impairment. 4. Intrusion Intrusion symptoms include: * involuntary memories * nightmares * flashbacks * psychological distress to reminders * physiological reactions to reminders. The defining quality is that the memory feels emotionally: HERE AND NOW rather than simply: THERE AND THEN. 5. Flashbacks Are More Than Remembering At the severe end of intrusion, the person may temporarily experience the traumatic event as though it is recurring. Awareness of the present can become partially or completely overshadowed. This makes dissociative re-experiencing qualitatively different from ordinary autobiographical memory. 6. Avoidance Avoidance can target: Internal reminders * memories * thoughts * feelings. External reminders * places * people * conversations * activities * objects * situations. Avoidance initially reduces distress but may prevent corrective learning. 7. Avoidance Can Generalise Fear often spreads beyond the original danger. For example: battlefield danger may generalise to: uniforms → loud noises → crowds → mail → public places The patient’s world progressively contracts. This represents inappropriate generalisation of threat. 8. Negative Cognitions and Mood This cluster includes: * inability to remember part of the trauma * persistent negative beliefs * distorted blame * persistent fear, horror, anger, g

  2. 2 days ago

    PSYCH 125: Gambling Disorder

    Medlock Holmes enters an immense Neo-Victorian casino called The House of the Endless Chase. At first, the place appears glamorous. Roulette wheels turn beneath chandeliers. Cards slide across green felt. Slot machines sing. Sports odds flicker across brass boards. Online betting screens glow in distant alcoves. But Holmes notices something that ordinary gamblers do not. Almost every corridor leads back to the tables. A sign above the entrance reads: “The first wager is about winning. The disorder is about continuing.” Gambling has existed across human history - dice, cards, lotteries, races, casinos, sports and now internet wagering. For most people it remains recreational. But for a vulnerable minority, gambling shifts from an activity into an addiction. That conceptual shift is important. Gambling disorder was historically grouped with impulse-control disorders. DSM-5 moved it into the category of non-substance-related addictive disorders, reflecting evidence that its behavioural patterns, reward circuitry, craving, impaired control and relapse resemble substance addictions. Holmes enters the first chamber and sees nine great levers controlling the disorder. The gambler needs increasingly large wagers for excitement. Attempts to cut down produce restlessness and irritability. Repeated promises to stop fail. Thoughts become consumed by gambling. Dysphoria triggers further play. Losses are chased. Lies conceal the extent of involvement. Relationships and occupations are jeopardised. Money is sought from others to rescue the financial consequences. Four or more of these features over a twelve-month period establish the diagnosis in the framework described by the source. Yet Holmes quickly realises that one feature dominates the whole casino: CHASING LOSSES. A person loses £100 and returns to recover it. Then £500. Then £5,000. The original goal was profit. Now the goal becomes escape from loss. But every attempt to escape creates a deeper loss. The gambler begins moving money between credit cards, family accounts, loans, savings and borrowed funds. What was once financial planning becomes the machinery that sustains the chase. The casino contains no clocks. That is appropriate. The pathological gambler increasingly lives in an eternal present. Future consequences - debt, divorce, unemployment, prosecution - become psychologically distant compared with the immediate possibility of the next wager. Holmes now understands the word repeatedly used in the chapter: Action. The gambler is not merely seeking money. The wager itself generates arousal. Anticipation. Risk. Possibility. The moment before the outcome becomes intensely rewarding. Winning allows continued gambling. Losing creates pressure to recover. Either outcome can feed the next bet. This helps explain why severe gambling disorder can eventually continue even when gambling itself brings little genuine pleasure. Holmes then enters the Cognitive Distortion Hall. A player remembers spectacular wins while forgetting hundreds of losses. Another believes five consecutive losses mean a win must now be due. Another interprets a near miss as evidence that success is getting closer. Another exaggerates personal skill in an activity dominated by chance. Another sees patterns where none exist. The casino exploits these cognitive vulnerabilities expertly. Lights. Sounds. Near misses. Free drinks. Rewards for prolonged play. “Comps.” Constant availability. Online access. Every feature encourages another wager. The next chamber contains the brain. Reward and decision-making circuits illuminate across the prefrontal cortex, striatum and mesolimbic dopamine system. Neuroimaging research suggests abnormalities in systems involved in reward processing, inhibition, judgement and decision-making. Gambling cues activate networks associated with craving. Real monetary risk recruits visual, cingulate, striatal and prefrontal regions. Dopamine becomes an especially important clue. Some people treated with dopamine agonists for Parkinson disease unexpectedly develop severe gambling behaviour despite no previous history of the disorder. In many, the gambling diminishes after the medication is withdrawn. The observation powerfully demonstrates that gambling behaviour is not simply a failure of morality. Biological vulnerability matters. But biology is not destiny. Two people can experience the same gambling environment and respond very differently. Genetics. Family exposure. ADHD. Mood disorder. Substance use. Personality. Social environment. Availability. Reinforcement. All influence vulnerability. Holmes next enters the Hall of Comorbidity. Depression. Bipolar disorder. Alcohol dependence. Cocaine use. Nicotine dependence. ADHD. Personality pathology. These conditions commonly accompany gambling disorder. Sometimes depression precedes the gambling. Sometimes catastrophic gambling debt produces depression. Sometimes each amplifies the other. The result can become extremely dangerous. Suicidal thinking is a major concern. For some people, disclosure of enormous debt, deception or criminal behaviour creates a catastrophic moment of exposure. Professional reputation collapses. Relationships fracture. The person sees no route out. Holmes writes one instruction above every consultation room: ASK ABOUT SUICIDE. He then studies the differential diagnosis. A gambling binge during mania is not automatically gambling disorder. Substance intoxication can temporarily disinhibit gambling. Psychosis can generate bizarre gambling behaviour. Dopamine agonists can precipitate excessive wagering. Antisocial behaviour may involve gambling for reasons quite different from addiction. And recreational gamblers - even enthusiastic ones - retain something crucial: Control. They establish limits. Losses remain acceptable. Life continues. The pathological gambler cannot reliably stop. Treatment begins not with moral condemnation but with engagement. This matters because denial is powerful. Many patients do not seek treatment until something external forces the issue: Divorce. Debt. Job loss. Arrest. Exposure. Psychotherapy therefore often begins with motivational interviewing. The question is not initially: “Why haven’t you stopped?” It is: “What has gambling begun to cost you?” CBT then targets triggers, distorted beliefs, craving, impulsive decision-making and the behavioural systems maintaining gambling. Patients learn to recognise: The gambler’s fallacy. Selective memory for wins. Illusions of control. Overconfidence. Near-miss thinking. Chasing. They also reconstruct life outside gambling. Relationships. Exercise. Work. Meaningful reward. Financial structure. Alternative sources of stimulation. Groups such as Gamblers Anonymous provide social support from people who understand the logic of the chase from inside it. Family and couple work may be essential because gambling disorder rarely damages only the gambler. Finances may require external safeguards. Access to cash may need restriction. Debts may need structured repayment. Casino or betting self-exclusion may help interrupt access. Medication has a supporting role rather than a single established pharmacological solution. The source discusses antidepressants, mood stabilisers, opioid antagonists such as naltrexone, and N-acetylcysteine, though outcomes vary and treatment of comorbidity may account for part of the benefit. Holmes finally reaches the deepest room. There is no roulette wheel. Only a staircase. At every step, the gambler can choose: Another wager or Stop the chase. The disorder repeatedly whispers: “One more bet will solve everything.” Recovery begins when the patient recognises the opposite: The next bet is not the solution to the previous loss. It is the mechanism that keeps the loss alive. Key Takeaways 1. Gambling Disorder Is an Addiction One of the most important changes in modern psychiatric classification was moving pathological gambling away from the impulse-control disorders. DSM-5 conceptualised it as a: NON-SUBSTANCE-RELATED ADDICTIVE DISORDER This reflects overlap with substance addictions in: * craving * impaired control * tolerance-like escalation * withdrawal-like distress * reward circuitry * persistence despite harm * relapse. 2. Gambling Is Ancient - Gambling Disorder Is Not New Humans have wagered for millennia. Historical forms include: * dice * knucklebones * animal contests * cards * lotteries * racing * gaming houses * casinos. Modern gambling adds: * electronic gaming machines * internet casinos * online poker * sports betting * fantasy betting * near-continuous mobile access. The technology changes. The behavioural reinforcement mechanisms remain recognisable. 3. Gambling Disorder Diagnostic Pattern The chapter describes nine core DSM-style criteria. A diagnosis requires four or more within 12 months. These include: Escalation Increasing amounts of money are wagered to achieve the desired excitement. Restlessness when reducing Attempts to stop or reduce gambling produce irritability or restlessness. Failed attempts to control Repeated unsuccessful efforts are made to cut down. Preoccupation The person’s mental life increasingly revolves around gambling. Gambling during dysphoria Gambling occurs when distressed, depressed or anxious. Chasing The individual returns to recover previous losses. Deception The extent of gambling is concealed from others. Jeopardising life roles Relationships, education or employment suffer. Financial rescue The person increasingly relies upon others for money because of gambling losses. 4. Chasing Losses Is a Central Mechanism Chasing occurs when the gambler responds to a loss by gambling more in an attempt to recover it. The sequence becomes: LOSS ↓ NEED TO RECOVER ↓ LARGER BET ↓ FURTHER LOSS ↓ GREATER URGENCY ↓ MORE GAMBLING This can become one of the most destructive loops in the disorder. 5. The “Action” Can Become More Important Than

  3. 3 days ago

    PSYCH 124: Obsessive-Compulsive and Related Disorders

    Medlock Holmes leaves the Grand Dispensary of Anxiety and enters an entirely different institution: The Grand House of Repetition. At first, everything appears orderly. Doors are locked. Hands are washed. Objects are aligned. Possessions are carefully preserved. Then Holmes notices something unsettling. The same actions are happening again. And again. And again. A man checks a locked door for the twentieth time. A woman washes already-clean hands. Another person stands before a mirror searching endlessly for an imperfection nobody else can see. Rooms disappear beneath possessions that cannot be discarded. In adjoining chambers, hair is repeatedly pulled and skin repeatedly picked. Above the entrance is written: “When repetition stops serving us, we begin serving the repetition.” This is the world of obsessive-compulsive and related disorders (OCRDs) - a diagnostic family that includes obsessive-compulsive disorder, body dysmorphic disorder, hoarding disorder, trichotillomania and excoriation disorder. Their grouping reflects important phenomenological and biological overlaps, while recognising that each disorder has its own characteristic focus. At the centre stands OCD. Holmes discovers its fundamental machinery: obsessions - recurrent, intrusive, unwanted thoughts, urges or images - and compulsions - repetitive behaviours or mental acts performed in response. The compulsion may reduce distress. But only temporarily. That relief reinforces the behaviour, helping the cycle continue. Yet OCD is more than excessive anxiety. Modern models increasingly describe disturbances in cognitive control, habit formation, error monitoring and cortico-striatal-thalamic-cortical circuitry. The orbitofrontal cortex, anterior cingulate and striatum become major clues. Holmes also discovers that insight exists on a spectrum. Many patients recognise that their fears are unreasonable. Others are less certain. A small minority become completely convinced of their obsessive beliefs. Poor insight does not automatically transform OCD into psychosis. The investigation then expands. In body dysmorphic disorder, repetition revolves around perceived defects in appearance. In hoarding disorder, difficulty discarding possessions gradually overwhelms living spaces. In trichotillomania, recurrent hair pulling becomes difficult to resist. In excoriation disorder, the repetitive behaviour is skin picking. Different objects. Different behaviours. But repeatedly, Holmes finds variations on a deeper theme: thought → urge → behaviour → temporary consequence → repetition. Treatment therefore aims to break the loop. For OCD, SSRIs and clomipramine provide important pharmacological tools, often at substantial therapeutic doses and for sufficiently long trials. But one of the most powerful interventions lies in deliberately confronting the very thing the disorder commands the patient to avoid. Exposure and Response Prevention - ERP. Exposure activates the feared uncertainty. Response prevention blocks the ritual. The patient learns that distress can be tolerated without obeying the compulsion and that catastrophic expectations need not determine behaviour. For severe treatment-resistant OCD, Holmes eventually reaches more specialised chambers: antipsychotic augmentation, glutamatergic strategies, intensive behavioural programmes and, in exceptionally refractory illness, neuromodulation or neurosurgical approaches. The lesson of the Grand House of Repetition is therefore hopeful. These disorders can become chronic and profoundly disabling. But the loop is not unbreakable. Key Takeaways 1. A New Diagnostic Family Obsessive-compulsive and related disorders became a distinct diagnostic grouping because these conditions share important features involving: * intrusive or repetitive thoughts * repetitive behaviours or mental acts * difficulties controlling repetitive behaviour * overlapping neurobiological mechanisms * overlapping treatment approaches. DSM-5-TR OCRDs include: * Obsessive-compulsive disorder - OCD * Body dysmorphic disorder - BDD * Hoarding disorder - HD * Trichotillomania - hair-pulling disorder * Excoriation - skin-picking disorder ICD-11 conceptualises the family somewhat more broadly and additionally incorporates conditions such as olfactory reference disorder and hypochondriasis within its OCRD framework. 2. Obsessive-Compulsive Disorder OCD is defined by: Obsessions, compulsions, or both. Obsessions Recurrent and persistent: * thoughts * urges * images that are experienced as: * intrusive * unwanted * distressing. The person commonly attempts to: ignore → suppress → neutralise them. Compulsions Repetitive: * behaviours or * mental acts that the individual feels driven to perform. Examples include: * washing * checking * ordering * counting * repeating * praying * mentally reviewing. 3. The Obsession–Compulsion Cycle A useful conceptual model is: INTRUSIVE THOUGHT ↓ THREAT / DOUBT / DISCOMFORT ↓ ANXIETY OR “NOT-JUST-RIGHT” FEELING ↓ COMPULSION ↓ TEMPORARY RELIEF ↓ REINFORCEMENT ↓ NEXT OBSESSION The ritual solves the immediate distress while helping preserve the longer-term disorder. 4. OCD Is Not Simply “Being Particular” Normal habits, preferences and routines are common. For OCD, symptoms must become sufficiently: * time-consuming * distressing * impairing. The diagnostic threshold includes symptoms taking more than one hour per day or causing clinically significant distress or functional impairment. 5. Major OCD Symptom Dimensions Symptoms commonly cluster around several dimensions. Contamination / Cleaning “What if I am contaminated?” → washing→ cleaning→ avoiding contact. Forbidden Thoughts / Checking Intrusive: * aggressive * sexual * religious * moral thoughts may generate checking, reassurance or mental rituals. Symmetry / Ordering The person may experience: “It isn’t right.” Objects or actions are repeated or arranged until they feel complete. Harm / Responsibility “What if I caused something terrible?” This may produce repeated: * checking * reviewing * reassurance seeking. Hoarding symptoms can also occur within OCD, although hoarding disorder is now diagnostically distinct. 6. OCD and Insight Insight exists on a continuum. Good or fair insight The patient recognises that OCD beliefs are probably or definitely untrue. Poor insight The patient believes the obsessive concern is probably true. Absent insight / delusional beliefs The patient is completely convinced. This distinction is clinically important. Absent insight does not automatically mean schizophrenia or another primary psychotic disorder. A small minority of people with OCD have absent insight. 7. Tic-Related OCD OCD can receive a: TIC-RELATED specifier. This means there is a current or previous tic disorder. Tic-related OCD tends to: * begin younger * occur more commonly in males * show more symmetry/ordering phenomena * involve sensory or premonitory urges * sometimes respond less strongly to SSRIs. Complex tics and compulsions can sometimes be difficult to distinguish. 8. Epidemiology OCD was historically thought to be rare. It is not. Its apparent rarity partly reflected: SHAME → CONCEALMENT → UNDERDIAGNOSIS The chapter reports a lifetime prevalence of approximately: 2.3% in a major epidemiological survey. Subclinical obsessive-compulsive symptoms are substantially more common. 9. Age of Onset Median onset is approximately: 19 years Around: 25% of cases begin by age 10. Early-onset OCD is more common in males and more frequently associated with tics. Onset after age 30 is comparatively unusual. Symptoms may also emerge or change during: * adolescence * pregnancy * the puerperium. 10. OCD Can Be Highly Disabling OCD can interfere profoundly with: * education * employment * relationships * family functioning * social participation * quality of life. A person may lose hours each day to rituals. Others restructure their entire lives around avoidance. Family members can become drawn into rituals through family accommodation. 11. Suicide Risk Matters Depression is a particularly important comorbidity. Suicidal thoughts can also occur in OCD. Therefore: Do not assume that OCD is merely an anxiety-and-ritual disorder. Routine clinical assessment should include: * depression * hopelessness * suicidal ideation * suicidal behaviour. 12. The Neurobiology of OCD Modern models increasingly conceptualise OCD as a disorder involving abnormalities of: COGNITIVE CONTROL and HABIT REGULATION rather than simply excessive anxiety. A central circuit is the: Cortico-Striatal-Thalamic-Cortical Circuit CORTEX ↓ STRIATUM ↓ THALAMUS ↓ CORTEX Important regions include: * orbitofrontal cortex * anterior cingulate cortex * striatum. Alterations in these circuits may contribute to difficulty: * inhibiting behaviour * shifting cognitive sets * monitoring errors * stopping established habits. 13. Goal-Directed Behaviour versus Habit A particularly useful model contrasts: Goal-directed action “I do this because it achieves something useful.” with: Habit-driven behaviour “I continue doing this even though it no longer achieves anything useful.” OCD appears to involve an excessive shift towards: HABIT-DRIVEN BEHAVIOUR This helps explain why patients can recognise that a ritual is unnecessary yet still feel compelled to perform it. 14. Fear Is Not the Whole Story Anxiety disorders are strongly associated with abnormal fear processing. OCD also involves other emotional processes, particularly: DISGUST Some contamination presentations may therefore involve exaggerated disgust processing rather than fear alone. Other patients describe: * incompleteness * tension * sensory discomfort * “not-just-right” experiences rather than conventional fear. 15. Neurochemistry Several neurotransmitter systems appear relevant: Serotonin The efficacy of serotonin reuptake inhibitors helped generate the influential serotonin hypothesis of

  4. 4 days ago

    PSYCH 123: Anxiety Disorders - Somatic Therapies

    Medlock Holmes enters an immense Neo-Victorian treatment complex called The Grand Pharmacological Dispensary of Anxiety. Rows of treatment pathways stretch before him. Some contain SSRIs and SNRIs. Others hold benzodiazepines, pregabalin, buspirone, beta-blockers, older antidepressants, antipsychotics, neurostimulation devices, and emerging experimental therapies. But Holmes immediately notices that the first room contains no medication at all. It is labelled: ASSESS BEFORE YOU PRESCRIBE. Not every anxious person needs pharmacological treatment. Some symptoms are transient or subsyndromal. At the same time, clinically significant anxiety disorders remain frequently under-recognised and undertreated, particularly in primary care. Patients may describe insomnia, palpitations, gastrointestinal symptoms, pain or fatigue rather than saying, “I am anxious.” Screening tools such as the GAD-7 can improve recognition. Treatment therefore begins with diagnostic precision. What is the primary disorder? How severe is it? Are there medical causes? Substance use? Depression? Other anxiety disorders? Psychosocial stressors? Previous treatment response? Drug interactions? Patient preference? Cost and access? The treatment-choice diagram on page 3 captures this broader logic: illness factors, patient factors and medication factors all contribute to the decision. For many anxiety disorders, SSRIs and SNRIs are the first-line pharmacological treatments. Holmes watches clinicians begin low and increase gradually. Why? Because anxious patients can experience an early transient increase in nervousness, agitation or insomnia. The medications also require patience. Some improvement may appear within two to four weeks, but an adequate therapeutic trial generally requires 8–12 weeks, and remission may take considerably longer. The goal is not merely partial improvement. It is remission, because residual symptoms continue to impair functioning and increase relapse risk. Holmes then reaches the Benzodiazepine Chamber. Here the effect is strikingly different. The alarm quietens rapidly. Benzodiazepines enhance GABAergic inhibition and can reduce anxiety quickly. That makes them valuable in selected circumstances - short-term adjunctive treatment, occasional panic, performance-related anxiety, or severe disabling symptoms when alternatives have failed or are not tolerated. But the chamber contains warning plaques: Sedation. Dependence. Withdrawal. Tolerance. Interaction with alcohol. Driving impairment. Their speed is both their strength and their danger. Next comes pregabalin. It has evidence particularly in GAD and can be useful when insomnia or pain coexist. Buspirone occupies another chamber, particularly for chronic generalized anxiety. Beta-blockers sit in a small performance hall. They do not treat generalized social anxiety. Instead, they reduce peripheral manifestations such as tremor and tachycardia during specific performance situations. Older agents remain available but sit farther down the treatment hierarchy. TCAs can work but carry more anticholinergic effects, cardiotoxicity and overdose risk. MAOIs can be highly effective, particularly phenelzine in panic and social anxiety, but dietary restrictions, drug interactions and safety concerns make them second-line options. Holmes then passes through individual disorder galleries. In GAD, SSRIs and SNRIs dominate first-line treatment, with alternatives such as pregabalin, buspirone and selected other agents. In panic disorder, SSRIs and venlafaxine are preferred initial options, while benzodiazepines may provide rapid short-term relief. In social anxiety disorder, SSRIs and SNRIs again feature prominently; pregabalin and clonazepam have evidence, while beta-blockers are mainly relevant to performance anxiety. In specific phobia, however, the shelves are nearly empty. The principal treatment is psychological - especially exposure therapy. Pharmacotherapy has little established role and benzodiazepines may even interfere with exposure learning. This tells Holmes something important: The presence of anxiety does not automatically imply that medication is the best treatment. The next room is labelled: TREATMENT RESISTANCE Before adding another medication, Holmes checks the foundations. Was the diagnosis correct? Was the dose adequate? Was the trial long enough? Is there thyroid disease? Substance use? Comorbid depression? Poor adherence? Drug interaction? Only then does he consider switching, augmentation, pregabalin, benzodiazepines, atypical antipsychotics or more experimental options. Beyond this room lies the Future Therapies Laboratory. rTMS. tDCS. Neurosteroids. Ketamine. Cannabinoids. Complementary therapies. Some show promise. But Holmes sees a large sign: PROMISING ≠ ESTABLISHED The evidence remains preliminary for many of these approaches. Finally, Holmes reaches the maintenance hall. The mistake here is stopping too soon. Anxiety disorders are frequently chronic or recurrent, and relapse after medication discontinuation is common. For many patients with chronic illness, medication may need to continue for 1–2 years after response, followed by gradual tapering rather than abrupt cessation. SSRIs and SNRIs can produce discontinuation symptoms, especially shorter-half-life agents such as paroxetine and venlafaxine. Holmes closes the final treatment ledger. The lesson is not that anxiety should simply be medicated. It is that somatic treatment should be deliberate, collaborative, evidence-based and disorder-specific. The right medication, for the right person, at the right dose, for the right duration, with careful monitoring - often alongside CBT - can transform disabling anxiety into something manageable. Key Takeaways Recognition before treatment * Anxiety disorders carry substantial personal and societal burden. * Not every anxious symptom requires somatic treatment. * Transient and subsyndromal anxiety should not automatically be medicalised. * Nevertheless, clinically significant anxiety disorders are commonly under-recognised and undertreated. * Detection in primary care has historically been below 50%. * Only a minority of recognised cases receive appropriate evidence-based treatment. * Patients commonly present with physical rather than psychological symptoms. * Reluctance to disclose emotional symptoms can contribute to missed diagnosis. * Clinicians may fail to enquire directly about anxiety. * Detection improves as severity increases and with repeated healthcare attendance. * Structured screening tools such as the GAD-7 improve recognition. * Anxiety can often be effectively managed in primary care when properly identified. * Chronic physical illness and adverse social determinants increase vulnerability and should heighten clinical suspicion. Principles of Pharmacological Management The chapter’s treatment principles can be summarised as: DIAGNOSE → ASSESS → EDUCATE → SELECT → MONITOR → OPTIMISE Important elements include: * establish the primary diagnosis * identify psychiatric comorbidity * identify medical comorbidity * review current medications and substances * assess psychosocial stressors * document baseline severity and frequency * perform appropriate physical examination and laboratory investigation * discuss treatment options * incorporate patient preference * consider previous personal and family treatment response * check drug interactions * consider affordability and access * monitor progress using validated scales. The figure on page 3 groups treatment selection into three broad domains: Illness Factors * severity * frequency * chronicity * comorbidity * situational versus generalized symptoms. Patient Factors * preference * adherence * insight * psychological-mindedness. Medication Factors * previous response * family response * drug interactions * access * cost. Pharmacotherapy versus Psychotherapy * Initial evidence-based options include pharmacotherapy, CBT, or both. * Acute efficacy of medication and psychological therapy may be similar in many anxiety disorders. * Long-term comparative evidence is less complete. * Combination treatment is intuitively attractive but has not consistently been proven superior to either treatment alone. * Sequential addition of CBT after partial medication response is often a pragmatic strategy. * Patient preference should meaningfully influence treatment choice. SSRIs and SNRIs These are the principal first-line pharmacological treatments across anxiety disorders. Common SSRIs include: * fluoxetine * sertraline * paroxetine * fluvoxamine * citalopram * escitalopram. Common SNRIs include: * venlafaxine * desvenlafaxine * duloxetine * levomilnacipran. Most guidelines favour an SSRI or venlafaxine as an initial antidepressant option. Start low, go slow Anxious patients can be particularly sensitive to early adverse effects. Initial treatment may temporarily increase: * nervousness * agitation * insomnia * tremor * gastrointestinal symptoms * headache * dizziness. Treatment is therefore usually started at a low dose and titrated gradually. Do not judge treatment too early * Early improvement may occur within 2–4 weeks. * A proper therapeutic trial generally requires 8–12 weeks at an adequate dose. * Some patients require substantially longer before remission. * The chapter notes that response or remission may sometimes take up to six months. Remission is the goal Partial response is not enough when substantial residual symptoms remain. Residual symptoms are associated with: * ongoing functional impairment * poorer quality of life * greater relapse risk. Treatment should therefore aim for: REMISSION + FUNCTIONAL RECOVERY rather than mere reduction in symptom score. SSRI/SNRI adverse effects Common effects include: * gastrointestinal disturbance * insomnia * nervousness * agitation * tremor * headache * dizziness * sexual dysfunction. Sexual dysfunction may involve: * reduced desire * impa

  5. 5 days ago

    PSYCH 122: Anxiety Disorders - Cognitive-Behavioural Therapy

    Medlock Holmes enters an immense Victorian experimental laboratory called The Institute of Fear and Learning. Around him, patients are trapped within apparently different mysteries. One avoids dogs. Another fears crowded trains because a panic attack might occur. Another rehearses every sentence before speaking, terrified of humiliation. Another spends hours worrying about disasters that may never happen. Yet Holmes notices the same mechanism running beneath them all. Threat → Anxiety → Escape or Safety Behaviour → Relief → Stronger Future Fear. Avoidance works remarkably well in the short term. That is precisely why it becomes such a problem. Each escape produces relief. Relief negatively reinforces avoidance. And every avoided encounter prevents the person from discovering something potentially transformative: Perhaps the predicted catastrophe would not have happened. Cognitive-behavioural therapy breaks this cycle. At its centre lies the concept of the fear structure: interconnected representations of stimuli, responses, and meanings. A dog becomes associated with danger. Palpitations become associated with heart attack. Social attention becomes associated with humiliation. Uncertainty becomes associated with intolerable catastrophe. The fear itself is not necessarily pathological. The problem is that the structure inaccurately represents reality. For therapeutic change to occur, two things are required. The fear structure must first be activated. Then the patient must encounter information incompatible with its pathological predictions. Modern formulations describe this in terms of prediction error: the brain predicts catastrophe, encounters a different outcome, and is given an opportunity to update its model. This explains why exposure sits at the heart of CBT for anxiety disorders. Exposure may be in vivo - entering the avoided lift, touching the feared animal, speaking in front of others. It may be imaginal - deliberately approaching distressing memories, images, thoughts, or feared future scenarios. Or it may be interoceptive - deliberately producing the bodily sensations that have themselves become feared, such as dizziness, breathlessness or a racing heart. But exposure is not simply a test of endurance. Its purpose is learning. The patient predicts: “If my heart races, something terrible will happen.” The experiment produces a racing heart. The catastrophe does not occur. Or perhaps something uncomfortable does happen - embarrassment, anxiety, uncertainty - and the patient discovers that even this is tolerable. The prediction begins to change. Holmes therefore realises that falling anxiety during a single exposure is not the ultimate objective. Someone may feel better because they distracted themselves, escaped psychologically, performed a ritual, sought reassurance, or relied upon another safety behaviour. The more important question is: What did they learn? That distinction also explains why safety behaviours matter. The patient who survives a feared situation while gripping a bottle of water, checking their pulse, rehearsing every sentence or staying beside a trusted companion may conclude: “I survived because my protection worked.” The old fear remains intact. CBT therefore combines exposure with cognitive work: identifying catastrophic predictions, examining evidence, using Socratic questioning, uncovering deeper meanings, and designing behavioural experiments that allow beliefs to collide with reality. Different anxiety disorders require different experiments. In panic disorder, treatment targets the fear of fear itself. Interoceptive exposure deliberately produces feared sensations so that palpitations, dizziness or breathlessness can be experienced without catastrophe. In specific phobia, the person progressively approaches the feared object or situation. In social anxiety disorder, exposure targets feared scrutiny and rejection while attention is shifted outward and safety behaviours are dropped. In generalized anxiety disorder, where there may be no single feared object, treatment focuses more heavily upon worry, intolerance of uncertainty, cognitive work, problem-solving and sometimes imaginal exposure to uncertain future outcomes. Acceptance and mindfulness can also be incorporated - not as methods of making anxiety disappear, but as ways of reducing the struggle against internal experience. By the end of the investigation, Holmes understands the paradox. The anxious person has often spent years becoming exceptionally skilled at preventing feared outcomes. CBT asks them to relinquish enough protection to discover whether that protection was ever necessary. The therapeutic question therefore changes from: “How can I make sure I never feel afraid?” to: “What happens when I approach what matters, allow anxiety to be present, and discover for myself what is actually dangerous?” That is the central experiment of cognitive-behavioural therapy. Key Takeaways 1. Anxiety disorders share a common CBT architecture Despite different symptom presentations, anxiety disorders commonly involve three interacting elements: Threat cognition → anxiety response → avoidance or defensive behaviour. The feared outcome differs by disorder: * Panic disorder: catastrophic consequences of anxiety or bodily sensations - the “fear of fear”. * Social anxiety disorder: embarrassment, negative evaluation and rejection. * Specific phobia: harm associated with a circumscribed object or situation. * GAD: uncertainty regarding future negative outcomes. * Similar CBT principles also extend to OCD and PTSD despite their classification outside the DSM-5 anxiety-disorders grouping. 2. The fear structure Emotional processing theory conceptualises fear as an interconnected structure containing: STIMULUS + RESPONSE + MEANING For example: Dog → tachycardia/urge to flee → “Dogs are dangerous and uncontrollable.” The structure is adaptive when it accurately identifies danger and generates effective protective behaviour. It becomes pathological when safe or relatively harmless stimuli, responses or situations acquire unrealistic meanings. 3. Emotional processing requires activation plus corrective information Two conditions are central: 1. Activate the fear structure. The patient must encounter or meaningfully represent what they fear. 2. Introduce incompatible information. Experience must provide evidence inconsistent with the pathological associations. Thus: Prediction → Experience → Prediction Error → Updating Exposure provides an especially powerful environment for this process. 4. Exposure is not simply about “getting used to anxiety” Exposure deliberately confronts feared but objectively safe: * objects * situations * activities * thoughts * memories * images * physiological sensations. Its therapeutic purpose is to alter the meaning attached to these experiences. The patient can learn: “Anxiety is uncomfortable, but tolerable.” “My prediction was exaggerated.” “The catastrophe did not occur.” “Even when something unpleasant happened, I could cope.” 5. Between-session learning matters more than simply feeling calmer during one exposure Earlier models emphasised within-session habituation - anxiety progressively declining during an exposure. The chapter cautions that this is neither necessary nor sufficient for successful treatment. Anxiety may decline because the patient: * distracts themselves * performs a compulsion * uses reassurance * engages in a safety behaviour * mentally disengages. The more meaningful evidence of emotional processing is enduring change that transfers beyond the immediate exercise, particularly between-session reductions in fear and pathological cognitions. 6. Avoidance is maintained by negative reinforcement The mechanism is simple: Fear → Escape → Relief Relief rewards escape. Therefore: Fear → Escape → Relief → More Escape Next Time Avoidance also prevents exposure to corrective information. The person concludes: “Nothing bad happened because I avoided it.” rather than discovering: “Perhaps it was safe.” This makes avoidance one of the central maintaining mechanisms of anxiety disorders. 7. Safety behaviours can preserve fear Safety behaviours are actions intended to prevent catastrophe during feared situations. Examples include: * reassurance seeking * checking * carrying “protective” objects * remaining near exits * rehearsing speech * monitoring bodily sensations * relying excessively on another person. The difficulty is misattribution. Instead of learning: “The feared situation was safe,” the patient learns: “I survived because I protected myself.” CBT therefore frequently requires dropping subtle safety behaviours during exposure. 8. Benzodiazepines can interfere with exposure learning The chapter describes research in fear of flying in which benzodiazepine use reduced anxiety during the initial exposure but impaired later learning when the medication was absent. The broader principle is important: Immediate reduction in distress is not synonymous with therapeutic learning. If medication, distraction or another safety strategy becomes the explanation for survival, the underlying fear prediction may remain unchanged. 9. Distraction is more nuanced Distraction does not invariably undermine exposure. Its effects depend upon factors such as: * intensity of distraction * divided versus complete attention * interpersonal involvement * severity of anxiety * number and duration of exposures. When emotion is overwhelming, some distraction may make engagement possible. The clinically important question remains whether sufficient processing and corrective learning occur. Three complementary models of exposure Emotional Processing Theory Pathological fear structures must be activated and modified through incompatible corrective information. Belief Disconfirmation Maladaptive beliefs generate emotional and beha

  6. 6 days ago

    PSYCH 121: Anxiety Disorders - Neuroimaging and Neuroanatomical Circuits

    Medlock Holmes enters the Grand Neuroanatomical Theatre of Fear. At the centre hangs an enormous transparent brain. The amygdala glows brightly. But Holmes does not stop there. Around it are the hippocampus. The medial and orbital prefrontal cortex. The anterior cingulate cortex. The insula. The thalamus. The hypothalamus. The bed nucleus of the stria terminalis. The periaqueductal grey. The locus coeruleus. Sensory association cortices. White-matter pathways. Every structure is connected. The chapter begins with an important methodological principle. To understand the circuitry of anxiety, investigators move step by step: First, identify the clinical phenomenon. Then identify the brain systems that normally perform that function. Then determine whether those systems behave differently in people with anxiety disorders. Finally, ask whether those abnormalities relate to symptoms, course, or treatment response. The functional problems are familiar: Persistent learning about threat. Exaggerated fear. Poor extinction. Difficulty suppressing attention to danger. Overgeneralisation from one threat to similar safe stimuli. Heightened perception of threat. Increased sensitivity to bodily sensations. Neuroimaging attempts to map these phenomena onto circuits. Holmes enters the Fear Learning Laboratory. A neutral cue appears. Then an aversive event. Again. And again. Eventually the cue alone produces fear. The cue has become the CS+. Another cue that was never paired with danger becomes the CS−. The amygdala learns the association. But then the experiment changes. The CS+ is repeatedly presented without the aversive event. Fear gradually decreases. This is extinction. Holmes notices something crucial. Extinction does not erase the original fear memory. It creates a new competing safety memory. That means extinguished fear can return. After time. In another context. After an unexpected aversive event. The fear memory was not destroyed. It was inhibited. The chapter distinguishes this from memory reconsolidation. When a fear memory is retrieved, it temporarily becomes unstable. During a reconsolidation window, new information may modify the original memory itself. This raises the possibility that future interventions might not simply suppress old fear, but update it. The clinical relevance is immediate. Exposure therapy works through these same learning principles. The therapeutic challenge is therefore not merely helping the patient endure fear. It is helping the brain encode and retain safety. Holmes now enters the Amygdala Chamber. Sensory information arrives through two major routes. The first is fast. The thalamus sends relatively crude information directly towards the lateral amygdala. Danger can be detected before the cortex has fully analysed what is happening. The second is slower. Sensory cortex processes the stimulus in greater detail before communicating with the amygdala. The lateral amygdala receives converging information about the conditioned and unconditioned stimuli. The basal and accessory basal nuclei help shape learning and memory. The central nucleus becomes the major output station. From there, signals descend towards the hypothalamus, brainstem, and motor systems. Heart rate rises. Blood pressure changes. Breathing accelerates. The body freezes or prepares to flee. Stress hormones are released. Facial expression changes. The figure on page 6 maps this architecture beautifully: external threat enters through sensory and thalamic pathways, converges upon the amygdala, and then recruits systems controlling endocrine, autonomic, behavioural, and motor responses. But Holmes notices another structure beside the amygdala: The Bed Nucleus of the Stria Terminalis. The distinction becomes fundamental. The amygdala is strongly involved in acute fear. The BNST is particularly important for sustained anxiety. An obvious danger appears. The amygdala responds. An uncertain threat may appear sometime soon. The BNST keeps the organism vigilant. This distinction becomes especially important in generalized anxiety disorder. Holmes then reaches the Prefrontal Control Room. The medial prefrontal cortex and anterior cingulate are not passive observers. They regulate fear. Interpret context. Predict consequences. Modify behaviour. Help determine whether the amygdala should continue sounding the alarm. The prelimbic and infralimbic regions in animal models provide an important conceptual framework. Prelimbic circuitry can support fear expression. Infralimbic circuitry contributes to extinction. In humans, the ventromedial prefrontal cortex performs an analogous regulatory role. The source’s figure on page 9 places fear expression and fear extinction beside one another. During fear expression, amygdala output activates downstream physiological responses. During extinction, hippocampal contextual information and infralimbic/vmPFC pathways recruit inhibitory interneurons within the amygdala, suppressing central-amygdala output. The same fear cue can therefore produce a very different response depending on which circuit dominates. Holmes sees anxiety as a problem of balance. Threat detection must be fast enough to protect. But cortical regulation must be strong enough to stop fear when the danger is no longer relevant. The next chamber belongs to the hippocampus. The amygdala asks: “Is this dangerous?” The hippocampus adds: “Where are we?” Context matters. A person bitten by a dog may learn fear. But whether that fear is expressed later depends partly on whether the current environment resembles the original context. The hippocampus helps distinguish: This place was dangerous. This place is safe. This cue used to predict harm. Here, it no longer does. Without contextual discrimination, fear generalises. The same signal spreads across places and situations that were never dangerous. The hippocampus therefore helps determine whether the original fear memory or the newer extinction memory should dominate. Holmes then encounters the Orbitofrontal Chamber. The orbitofrontal cortex tracks changing reinforcement. What used to predict danger may no longer do so. What used to be safe may now carry risk. Behaviour must change accordingly. Damage to orbitofrontal systems produces perseveration. The person continues using an old strategy despite changed circumstances. In anxiety, dysfunctional orbitofrontal regulation may contribute to continued fearful thoughts and behaviours even when reinforcement no longer supports them. The next room belongs to the insula. Here, Holmes hears the body. Heartbeat. Breathing. Nausea. Chest tightness. Internal temperature. Visceral sensations. The insula plays a central role in interoception. This is particularly relevant to panic disorder. The person does not merely experience bodily sensations. They monitor them. Interpret them. Amplify them. A harmless change in heart rate becomes evidence of catastrophe. The brain’s representation of internal bodily state becomes part of the threat itself. Holmes enters the Imaging Observatory. Different instruments examine different dimensions of brain structure and function. Structural MRI measures regional size and shape. Voxel-based morphometry compares grey-matter architecture. Diffusion tensor imaging estimates white-matter organisation through measures such as fractional anisotropy. PET examines blood flow or metabolism. fMRI measures BOLD signal. EEG records electrical activity. MEG measures magnetic fields generated by neuronal activity. But Holmes quickly learns that brain imaging is always state dependent. A resting brain. A brain viewing fearful faces. A brain recalling panic. A brain anticipating shock. A brain undergoing treatment. These are not equivalent experiments. Neuroimaging therefore depends as much on the task as on the scanner. The next chamber examines healthy fear learning. Human studies repeatedly show increased amygdala activity to a CS+ compared with a CS−. During extinction, vmPFC activation becomes important. Stronger vmPFC activation predicts better retention of extinction. The hippocampus becomes particularly active when context determines whether fear or safety should be expressed. Together, the amygdala, vmPFC, and hippocampus form a central circuit for human fear acquisition and extinction. Holmes then enters the Emotional Face Gallery. Hundreds of faces look towards him. Fearful. Angry. Happy. Neutral. Surprised. The amygdala responds to many emotionally salient expressions, but fearful and ambiguous faces can produce particularly strong responses. Why? A fearful face says: “Something dangerous is nearby.” But it does not reveal what the danger is. Uncertainty itself becomes salient. Even when fearful faces are presented too briefly for conscious recognition, the amygdala can still respond. Threat processing can therefore occur before explicit awareness. The anterior cingulate detects conflict. The lateral prefrontal cortex helps redirect attention. The insula monitors bodily state. The amygdala enhances memory for emotionally salient events. Holmes sees why anxiety can become so persistent. The brain not only detects threat. It can preferentially remember it. The investigation now turns to individual disorders. The first chamber is Panic Disorder. Holmes must explain something unusual. Why does panic sometimes appear to occur without any trigger? One theory suggests a false alarm. Normal fear circuitry activates inappropriately because of abnormalities in internal homeostatic systems. Another theory suggests failed regulation. A small anxiety response begins but cortical systems fail to contain it. A third possibility is that the trigger exists, but is processed outside conscious awareness. The patient experiences the attack as spontaneous. The brain may have detected something the conscious mind did not. Neuroimaging in panic disorder shows abnormalities across hippocampal and parahippocampal regions, te

  7. 6 days ago

    PSYCH 120: Anxiety Disorders - Neurobiology and Neuroscience

    Medlock Holmes enters the Neurobiological Citadel of Fear. At its centre stands an enormous transparent brain. It is not silent. Signals move constantly between the amygdala, hippocampus, prefrontal cortex, thalamus, hypothalamus, locus coeruleus, and brainstem. Some pathways detect threat. Others generate autonomic responses. Others encode memories. Others decide whether a stimulus is dangerous. Others determine whether the alarm can finally be switched off. Holmes immediately sees the problem. Anxiety is not produced by a single fear centre. It is produced by a network. The central diagram on page 4 captures this clearly. The thalamus contributes to autonomic and endocrine regulation. The hippocampus and amygdala participate in salience detection and associative learning. The locus coeruleus projects widely to cortex and helps regulate attention, arousal, and pain evaluation. The prefrontal cortex helps coordinate higher-order regulation of these responses. The first chamber belongs to norepinephrine. The locus coeruleus sits in the pons like an emergency broadcasting tower. When danger appears, norepinephrine surges. Heart rate increases. Pupils dilate. Breathing accelerates. Attention narrows. Vigilance rises. The organism becomes ready to fight or flee. In the short term, this is adaptive. But when the noradrenergic system becomes excessively active, the same protective response can become pathological. The person remains hyperaroused when danger has passed. Startle becomes excessive. Attention remains locked onto threat. Autonomic symptoms themselves become frightening. This is particularly relevant to panic disorder and phobic states. Holmes sees the paradox. Drugs that increase norepinephrine acutely may provoke anxiety. Yet SNRIs and tricyclic antidepressants can treat anxiety disorders over time. The explanation lies in adaptation. Their therapeutic effects emerge not from the immediate increase in monoamine signalling, but from longer-term receptor and network changes. The next chamber is the HPA Axis Observatory. Stress activates the hypothalamus. CRH rises. ACTH follows. The adrenal glands release cortisol. Again, the system is protective. Cortisol mobilises energy. Sharpens vigilance. Modifies memory. Suppresses nonessential processes. Helps the organism survive an acute threat. But Holmes watches what happens when the system stays active for too long. Persistently elevated glucocorticoids affect the hippocampus. Cell survival changes. Morphology changes. Memory becomes impaired. Metabolic and cardiovascular effects accumulate. The source describes hypertension, osteoporosis, immunosuppression, insulin resistance, dyslipidaemia, coagulation abnormalities, and cardiovascular disease among the possible consequences of prolonged glucocorticoid exposure. Yet when Holmes compares patients with different anxiety disorders, he does not find one uniform HPA abnormality. Panic disorder shows mixed findings. GAD may show increased, decreased, or dysregulated cortisol activity. Some studies of long-term hair cortisol in GAD even suggest lower concentrations, raising the possibility that chronic anxiety can eventually downregulate the stress axis. Social anxiety also shows inconsistent findings influenced by age and sex. Specific phobias, however, can produce clear cortisol increases during exposure to the feared stimulus. The lesson is important: The stress system is dysregulated in anxiety, but not in one identical direction across all disorders. Holmes then enters the chamber of corticotropin-releasing hormone. CRH does more than activate cortisol. It operates throughout the brain. Amygdala. Prefrontal cortex. Cingulate cortex. Bed nucleus of the stria terminalis. Nucleus accumbens. Periaqueductal grey. Locus coeruleus. Raphe nuclei. CRH therefore coordinates behavioural as well as endocrine responses to stress. Early-life stress may alter CRH signalling for years. High CRH exposure can contribute to allostatic load. CRH-1 and CRH-2 receptors appear to have partly opposing functions. CRH-1 activation tends to increase anxiety-like behaviour in animal models. CRH-2 may contribute to more adaptive or anxiolytic responses. It appears biologically compelling. But clinical translation has been disappointing. CRH-1 antagonists have not yet produced reliable therapeutic success in anxiety disorders. Holmes writes another principle in his notebook: Biological plausibility does not guarantee clinical efficacy. The next chamber belongs to dopamine. Dopamine is usually associated with reward and motivation. But during stress it also changes. The medial prefrontal cortex is particularly sensitive. Moderate stress increases prefrontal dopamine. This can improve adaptive responding. Too much dopamine impairs cognition. Too little may delay extinction of conditioned fear. Holmes sees an inverted-U-shaped control system. Optimal dopamine allows flexible learning. Excessive dopamine destabilises cognition. Insufficient dopamine makes the brain slow to update when danger is no longer present. This becomes especially important in fear extinction. The person may know intellectually that the situation is now safe, but the defensive system fails to learn it. The next chamber is serotonin. Here the biology becomes even more complex. Serotonin can both promote and reduce anxiety depending on where in the brain it acts. In the prefrontal cortex and amygdala, serotonin can enhance awareness of threat. In the dorsal periaqueductal grey, it can suppress fight-or-flight behaviour. This dual role helps explain why serotonin can participate in panic, anticipatory anxiety, and generalized worry. The 5-HT1A and 5-HT2 receptor families are particularly important. Imaging studies show reduced 5-HT1A receptor binding in several regions in panic disorder and social anxiety. Early-life changes in serotonergic systems may have persistent effects on anxious behaviour. SSRIs eventually alter these circuits and remain among the most effective treatments for panic disorder, social anxiety disorder, and GAD. But again, the effect is delayed. The immediate neurochemical change is not the same as the final therapeutic change. Holmes then enters the GABA Chamber. Here everything becomes quieter. GABA is the major inhibitory neurotransmitter in the brain. It reduces neuronal excitability. It restrains the alarm. The GABA-A receptor sits at the centre of the chamber. Benzodiazepines bind allosterically to this receptor complex and amplify inhibition. Anxiety falls quickly. The person relaxes. Panic diminishes. But the chamber contains a warning. Tolerance. Dependence. Sedation. Memory effects. Abuse potential. This explains why benzodiazepines, despite their clear anxiolytic efficacy, are no longer considered first-line treatment for panic disorder, social anxiety disorder, or GAD. Holmes also notices something interesting. Flumazenil - a benzodiazepine antagonist - can provoke panic in people with panic disorder but not reliably in healthy controls. This suggests that the GABA system is not merely a target for treatment. It may already be altered within the disorder itself. The next chamber belongs to glutamate. The excitatory counterpart to GABA. Holmes watches the balance shift: GABA inhibition ↓ Glutamate excitation ↑ The alarm system becomes easier to trigger. Glutamate also interacts with norepinephrine and serotonin. NMDA receptors become particularly important because they are involved in both fear acquisition and fear extinction. Block NMDA receptors and fear learning can be impaired. But extinction can also be impaired. That produces a therapeutic puzzle. How do we reduce pathological fear without preventing the brain from learning safety? One answer emerged through D-cycloserine. Rather than acting as a traditional anxiolytic, it partially stimulates the glycine site of the NMDA receptor. The hope was that it could enhance the learning that occurs during exposure therapy. Early trials were promising. Acrophobia. Social anxiety. Panic disorder. But larger studies produced inconsistent findings. Again, Holmes sees the translational challenge: A molecule may enhance learning. But the quality and timing of the learning experience still matter. If exposure goes badly, enhancing learning could theoretically reinforce the wrong memory. Ketamine enters the story from another direction. Small preliminary studies suggest rapid reductions in refractory social anxiety and generalized anxiety symptoms. But this evidence remains limited. Other glutamatergic drugs have produced similarly mixed or preliminary results. The source repeatedly reminds Holmes not to confuse promising mechanism with established treatment. The next room is filled with hormones derived from cholesterol. These are neurosteroids. Allopregnanolone. Pregnanolone. Other progesterone metabolites. They modulate GABA-A receptors and may provide endogenous anxiolytic effects. The biology becomes particularly striking during pregnancy and the postpartum period. Progesterone and allopregnanolone rise during pregnancy. Some women with panic disorder experience improvement. Hormone concentrations fall rapidly after delivery. Anxiety may rebound. The source explores this as one example of how endogenous neurosteroid systems may influence fear and anxiety. Holmes moves onward. The next chambers contain an expanding collection of neuropeptides. Vasopressin. Oxytocin. Neuropeptide Y. Galanin. Cholecystokinin. Each modifies the stress system differently. Oxytocin is particularly associated with social behaviour, social cognition, and attenuation of stress responses. Intranasal oxytocin has reduced amygdala responses to fearful faces and altered social-anxiety circuitry in experimental studies. It may facilitate extinction of social fear. But clinical implementation remains uncertain. Neuropeptide Y appears to play a different role. Resilience. Stress buffering. Fear-memory modulation. Higher

  8. 11 Sept

    PSYCH 119: Anxiety Disorders - Epidemiology

    Medlock Holmes enters the Global Atlas of Anxiety. At the centre floats an enormous illuminated globe. Every continent is marked. Every age group is represented. And across the map, the same message appears: Anxiety disorders are everywhere. Epidemiology asks more than how many people are affected. It asks: Who develops anxiety? When does it begin? Which disorders persist? What travels with them? Which people receive treatment - and which remain invisible? Holmes begins with a warning. Clinical populations show only the tip of the iceberg. People reaching specialist services are often more severely ill, more impaired, and more likely to have multiple disorders than people with anxiety in the wider community. To understand the true magnitude of anxiety disorders, Holmes must leave the clinic and investigate entire populations. The first chamber contains the world’s largest epidemiological surveys. The WHO World Mental Health initiative spans more than 25 countries and over 130,000 participants. Across studies, anxiety disorders repeatedly emerge as the most prevalent class of mental disorders. But rates vary considerably between countries. The international table on page 5 illustrates this clearly. Panic disorder, agoraphobia, social anxiety disorder, specific phobia, and GAD all show substantial cross-national variation. For example, 12-month social anxiety estimates range from around 0.2% in Nigeria to 7.1% in one United States survey, while lifetime specific-phobia estimates range from approximately 1.5% in Italy to 10.8% in New Zealand. Holmes is careful not to assume that every difference is biological. Language. Translation. Diagnostic thresholds. Cultural interpretation. Interview technique. Sampling. All can change measured prevalence. Epidemiology therefore measures not only illness. It also measures the instruments used to detect it. The next gallery belongs to children and adolescents. Here the finding is even more striking. A meta-analysis across 27 countries estimated a pooled 12-month prevalence of any anxiety disorder at approximately 6.5% in young people. The US National Comorbidity Adolescent Supplement found lifetime anxiety rates of 31.9% in adolescents, compared with 28.8% in adults. The comparison table on page 7 shows that adolescents actually had higher aggregate 12-month anxiety prevalence than adults: 24.9% versus 18.1%. Holmes realises why. Anxiety disorders begin early. The median age of onset across the major anxiety disorders is approximately 12 years in adult retrospective surveys, while adolescent data suggest an even earlier median around 6 years. But each anxiety disorder has its own developmental clock. Separation anxiety and specific phobias often emerge in middle childhood. Social anxiety becomes prominent in adolescence. Agoraphobia and panic disorder peak from late adolescence into young adulthood. GAD tends to emerge later, often in young adulthood. The disorders therefore unfold like different constellations appearing at different points in development. The investigation next turns to sex differences. Women have approximately twice the lifetime rates of panic disorder, GAD, agoraphobia, and specific phobia compared with men in many community studies. Girls also show higher rates of most anxiety disorders. The difference persists across the lifespan, becoming particularly pronounced in early and middle adulthood. But epidemiology cannot yet fully explain why. Biology. Hormonal influences. Temperament. Stress exposure. Social roles. Behavioural conditioning. Cultural expectations. All may contribute. Holmes then enters the Risk Observatory. One instrument is labelled: Behavioural Inhibition Some children react strongly to novelty. They withdraw. Freeze. Watch carefully. Show increased physiological arousal. Behavioural inhibition can represent an early vulnerability to later anxiety. Another instrument measures: Anxiety Sensitivity This is not simply anxiety. It is fear of the sensations of anxiety themselves. A racing heart becomes: “I am having a heart attack.” Dizziness becomes: “I will faint.” Visible trembling becomes: “Everyone will see that I cannot cope.” Anxiety sensitivity predicts later anxiety symptoms and disorders more specifically than depression. The chapter then turns to families and genes. Anxiety disorders aggregate within families. Twin and family studies show meaningful genetic contributions. But heritability is moderate rather than absolute. Environment matters greatly. Genes may influence autonomic reactivity. Behavioural inhibition. Startle. Respiratory sensitivity. Social fear. But what ultimately emerges depends upon development and experience. Holmes sees anxiety as neither inherited destiny nor learned behaviour alone. It is an interaction. The next chamber is labelled: COMORBIDITY The room is crowded. Anxiety disorders cluster with one another. They also overlap with: Mood disorders. Substance-use disorders. Eating disorders. Disruptive behaviours. Physical illnesses. The relationship with depression is particularly important. Anxiety frequently appears first. Depression follows later. Family and twin studies suggest that panic disorder, GAD, and depression may share part of their familial and genetic liability. Anxiety may therefore sometimes represent an early developmental expression of a vulnerability that later appears as depression. Holmes then enters the Medical Wing. Diabetes. Cardiovascular disease. Respiratory illness. Epilepsy. Migraine. Multiple sclerosis. Parkinson disease. Medical comorbidity is especially strong for panic disorder and GAD. But causality is complicated. Anxiety may share biological vulnerability with the medical disorder. It may develop in response to disability. It may arise from treatment. Or the presence of both illnesses may simply increase the likelihood that a patient reaches medical care. The epidemiologist must distinguish association from explanation. The next chamber concerns life experience. Trauma and stressful events can precipitate anxiety. But the relationship is not simple. Some phobias appear after frightening experiences. Others arise without any obvious precipitating event, possibly reflecting evolutionary preparedness. Humans may be biologically easier to condition towards certain ancient threats. Snakes. Spiders. Heights. Dangerous environments. Yet another person can encounter the same threat and recover completely. The ability to extinguish fear may therefore be just as important as the ability to acquire it. Stressful events can also interact with inherited vulnerability. The event is not always the cause. Sometimes it is the trigger. Holmes now reaches the Course Observatory. Not all anxiety disorders behave alike. Phobic disorders, particularly social anxiety, tend to show greater stability. GAD and panic symptoms fluctuate more over time. Persistence is more likely when anxiety is severe, longstanding, poorly responsive to treatment, and accompanied by particular psychological vulnerabilities. Longitudinal studies reveal another uncomfortable truth: Anxiety beginning in childhood can shape adult life. The 15-year Smoky Mountains follow-up found that childhood anxiety predicted later difficulties in health, finances, and relationships. The pattern differed by diagnosis. Young people with GAD showed broad impairment. Those with social phobia showed particularly strong interpersonal difficulty. Those with separation anxiety showed more later health problems. Anxiety is therefore not simply a childhood phase when it becomes clinically significant. It can alter the trajectory of development. The final chamber contains an enormous brass balance labelled: GLOBAL BURDEN One side carries: Years Lived with Disability The other: Years of Life Lost The source reports approximately 370 years lived with disability per 100,000 population attributable to anxiety disorders. Total disability-adjusted life-year estimates are approximately 459 for females and 282 for males, with peak disability concentrated between ages 10 and 24 years. Anxiety is described as the eighth leading cause of years lived with disability in the global burden estimates discussed in the chapter. Holmes looks beyond the numbers. Missed school. Reduced educational achievement. Absence from work. Restricted relationships. Substance use. Physical illness. Lost opportunities. And, for a minority, suicide. The burden is amplified because anxiety begins so early and can persist for so long. Yet the final mystery is the most frustrating. Effective treatments exist. CBT works. Pharmacological treatments work. But enormous numbers of people never receive them. The treatment gap remains global. Holmes closes the atlas. Epidemiology has revealed that anxiety disorders are not peripheral illnesses. They are among the central public-health problems of psychiatry. The most important discovery may therefore be not how common anxiety is. It is how early it begins, how long its consequences can persist, and how many people remain untreated despite living for years within reach of effective care. Key Takeaways * Epidemiology examines the distribution and determinants of disease within populations. * Descriptive epidemiology studies disease according to person, place, and time. * Analytic epidemiology examines determinants and potential causal factors. * Case-control studies compare people with and without a disorder to identify associated exposures or risk factors. * Cohort studies follow exposed and unexposed groups over time to compare disease incidence. * Community samples are essential because clinical samples often represent only the tip of the iceberg. * People seen in specialist settings generally have more severe illness, more comorbidity, and greater impairment than untreated community cases. * Epidemiology has contributed structured and semistructured diagnostic interviews to psychiatry. * Population studies have clarified

See All (691)

Trailer

About

Clinical Deep Dives is a Medlock Holmes podcast for clinicians and learners who want understanding, not just information. Using classic medical and surgical texts as a guide and the generative power of AI, each episode explores ideas with curiosity and clarity, designed for learning on the move and knowledge that actually sticks. drmanaankarray.substack.com

Information

  • Creator
    Med School Audio - Medical Knowledge Reimagined & Learning Made Memorable.
  • Years Active
    2026
  • Episodes
    691
  • Rating
    Clean
  • Copyright
    © Dr Manaan Kar Ray
  • Show Website
    Clinical Deep Dives